Arvinas (NASDAQ:ARVN) Stock Price Down 4.6% - Should You Sell?

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report)'s stock price fell 4.6% on Wednesday . The stock traded as low as $7.67 and last traded at $7.65. 711,703 shares were traded during mid-day trading, a decline of 51% from the average session volume of 1,467,152 shares. The stock had previously closed at $8.02.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Morgan Stanley decreased their price target on shares of Arvinas from $12.00 to $11.00 and set an "equal weight" rating for the company in a report on Friday, May 9th. Leerink Partners reaffirmed a "market perform" rating and issued a $9.00 price target (down from $10.00) on shares of Arvinas in a research note on Monday, June 2nd. Leerink Partnrs cut shares of Arvinas from a "strong-buy" rating to a "hold" rating in a research note on Sunday, June 1st. TD Cowen downgraded Arvinas from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. Finally, Wells Fargo & Company dropped their price target on Arvinas from $26.00 to $19.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. Ten research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $20.29.

Arvinas Stock Performance

The business has a fifty day simple moving average of $7.25 and a 200 day simple moving average of $11.71. The stock has a market cap of $585.74 million, a price-to-earnings ratio of -12.12 and a beta of 2.17.

Arvinas (NASDAQ:ARVN - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $1.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.93) by $2.07. Arvinas had a negative return on equity of 7.74% and a negative net margin of 10.92%. During the same period last year, the business posted ($0.97) earnings per share. Arvinas's quarterly revenue was up 646.2% on a year-over-year basis. On average, equities research analysts anticipate that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Andrew Saik sold 5,700 shares of the company's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $7.61, for a total value of $43,377.00. Following the completion of the transaction, the chief financial officer directly owned 164,401 shares of the company's stock, valued at approximately $1,251,091.61. This represents a 3.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.73% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ARVN. GF Fund Management CO. LTD. bought a new position in shares of Arvinas during the 4th quarter worth about $28,000. GAMMA Investing LLC raised its position in shares of Arvinas by 11,283.8% in the first quarter. GAMMA Investing LLC now owns 4,212 shares of the company's stock worth $300,000 after buying an additional 4,175 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its position in Arvinas by 965.4% during the first quarter. Caitong International Asset Management Co. Ltd now owns 4,656 shares of the company's stock valued at $33,000 after purchasing an additional 4,219 shares in the last quarter. CWM LLC increased its holdings in shares of Arvinas by 2,317.5% in the first quarter. CWM LLC now owns 7,615 shares of the company's stock worth $53,000 after buying an additional 7,300 shares during the period. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of Arvinas in the fourth quarter worth about $171,000. 95.19% of the stock is currently owned by institutional investors and hedge funds.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.